Investor Update December 2017


Message From The CEO

Welcome to the first Sienna Cancer Diagnostics investor update since our listing in August. We will provide updates when applicable to keep you informed of our growth, and execution of plans. Read More >


The Bladder Cancer Diagnostic Market

The first application of Sienna’s IVD test is as an adjunct to urine cytology to assist in the diagnosis of bladder cancer. Urine cytology is the standard non-invasive test to investigate whether a patient may have bladder cancer. Sienna estimates there are approximately 1.5 million urine cytology tests performed annually in the United States alone. Therefore, the worldwide market for our test presents a substantial opportunity. More >

Q&A with Mark Rees

PhD, VP of Advanced Diagnostics, StatLab Medical Products

Dr Mark Rees has served as Vice President Advanced Diagnostics at StatLab since January 2014. Mark’s current role involves the development and implementation of the Company’s strategic plan for its new product line of Advanced Diagnostics. We recently sat down with Mark and asked him how Sienna’s product fit into StatLab’s growth strategy and how our product is being received by pathologists in the US. Read Q&A >

What We Do and Why We Exist

We are a medical technology company that develops and commercialises novel diagnostic tests for the pathology laboratory market. The initial product developed and brought to market by Sienna is the first in-vitro diagnostic (IVD) test for detection of hTERT, a component of the cancer-related biomarker, telomerase. While telomerase is now well recognised and understood, there has never been a clinical diagnostic test available to detect its presence in specific cells of interest. Read More >

IIR Research Report Puts 31 Cent Target on Sienna

Last month, Independent Investment Research (IIR) initiated coverage on Sienna. The report recognises Sienna as the first company to develop an IVD product for the detection of hTERT.IIR assigned Sienna a target price of $0.31, on a valuation range up to $0.81, with the high-end of the valuation range based on more aggressive market penetration assumptions. Read Report >

StatLab Distribution

In order to gain the fastest possible sales traction in the US market and minimise direct costs, it was determined that a supply and distribution partner model would provide the optimal solution. StatLab Medical Products, our exclusive distribution partner in the United States, manages the sales, marketing and support of our IVD test in the US. The StatLab team has been promoting Sienna’s hTERT test to the US pathology laboratory market since around March 2017. Initial interest has been positive with several laboratories having already commenced their own in-house evaluation of the product. Read More >

Appointment of Exclusive Distributor for Denmark and Sweden

In September, Sienna appointed Axlab A/S as our exclusive distribution partner for Denmark and Sweden, in accordance with our plan to broaden and accelerate the global rollout of its IVD test for the detection of hTERT. This agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories throughout those countries. Read More >

Sienna Teams up With UoM to Provide Future Innovators Hands-on Experience

We are passionate about our work at Sienna and actively engage in the development of young people seeking to establish careers in the industry. An example of this engagement is Sienna’s participation in the University of Melbourne’s internship program, which is undertaken by final-year Master of Biotechnology students. Interns in the program get an insight into how a science-based company actually operates, and contribute in ways that provide genuine results for the company. To understand how and why we’re working with interns. Read More >

Sienna in The News – Recent Media Articles

To view the list of media articles in which Sienna has appeared, Click Here >
Copyright © 2017 WE Buchan, All rights reserved.


No Very

Captcha Image

Sign up for updates